New results from AlzeCure’s pain project TrkA-NAM presented at the IASP pain conference

New results from AlzeCure’s pain project TrkA-NAM presented at the IASP pain conference

AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops a broad portfolio of drug candidates for diseases affecting the central nervous system, with projects in both Alzheimer’s disease and pain, today announced that the company’s presentation and poster on its preclinical project TrkA-NAM for osteoarthritic pain and other severe pain disorders, which were presented at the IASP 2021 World Congress on Pain June 9-11 and 16-18, are now available in full on the company’s website.

The poster presentation, given by Dr. Pontus Forsell, Head of Discovery at AlzeCure and project leader of the TrkA-NAM project, concludes that the NGF/TrkA pathway is a well validated and a promising alternative for new analgesics without the side effects and dependency issues observed with opioids. Identification of selective and potent TrkA-NAM’s could potentially avoid some of the side effects observed for anti-NGF antibodies due to a more selective mechanism of action, while retaining the analgesic efficacy. The lead optimization program has identified very potent and selective TrkA-NAM’s and demonstrated pain relief in preclinical models in vivo, both in neuropathic pain and arthritis suggesting a broad indication potential.
 
“The data presented in the poster presentation is very promising and a clear validation of our R&D platform. Our work to select a drug candidate for this highly interesting project continues, and we expect to announce a candidate before the end of 2021,” said Martin Jönsson, CEO of AlzeCure Pharma AB.
 
The authors for the late-breaking abstract, titled Negative Allosteric Modulators of TrkA for the Treatment of Pain include Dr. Pontus Forsell, Head of Discovery at AlzeCure, Dr. Gunnar Nordvall, Head of Chemistry at AlzeCure, Dr. Magnus Halldin, Head of DMPK & Safety Assessment at AlzeCure, and Dr. Johan Sandin, CSO at AlzeCure.
 
The poster and recorded presentation are available on AlzeCure’s website: https://www.alzecurepharma.se/en/presentations-and-interviews/

For more information, please contact

Martin Jönsson, CEO
Tel: +46 707 86 94 43
martin.jonsson@alzecurepharma.com

About AlzeCure Pharma AB (publ)

About AlzeCure Pharma AB (publ)
AlzeCure® is a Swedish pharmaceutical company that develops new innovative drug therapies for the treatment of severe diseases and conditions that affect the central nervous system, such as Alzheimer’s disease and pain – indications for which currently available treatment is extremely limited. The company is listed on Nasdaq First North Premier Growth Market and is developing several parallel drug candidates based on three research platforms: NeuroRestore®, Alzstatin® and Painless.

NeuroRestore consists of two symptomatic drug candidates where the unique mechanism of action allows multiple indications, including Alzheimer’s disease, as well as cognitive disorders associated with traumatic brain injury, sleep apnea and Parkinson’s disease. The Alzstatin platform focuses on developing disease-modifying and preventive drug candidates for early treatment of Alzheimer’s disease and comprises two candidates. Painless is the company’s research platform in the field of pain and contains two projects: ACD440, which is a drug candidate in the clinical development phase for the treatment of neuropathic pain, and TrkA-NAM, which targets severe pain in conditions such as osteoarthritis. AlzeCure® aims to pursue its own projects through preclinical research and development to early clinical phase, and is continually working on business development to find suitable outlicensing solutions with other pharmaceutical companies.

FNCA Sweden AB, +46(0)8 528 00 399 info@fnca.se, is the company’s Certified Adviser. For more information, please visit www.alzecurepharma.se.
 
About TrkA-NAM
The TrkA-NAM project, which is in research phase, is aimed at treatment of osteoarthritis pain and other severe pain disorders and has strong preclinical and clinical validation.

For the TrkA-NAM drug project, we have leveraged our knowledge concerning the underlying biology for the NeuroRestore platform in order to develop new compounds that focus on providing pain relief in conditions associated with severe pain.

The goal of the project is to develop a small-molecule TrkA-negative allosteric modulator for the treatment of osteoarthritis pain and other severe pain disorders. The global osteoarthritis market is expected to reach USD 11.0 billion by 2025, from USD 7.3 billion in 2020. Growth in this market is driven by factors such as the increasing occurrence of osteoarthritis, the growing aging population, and an increase in the number of sports injuries. Over 240 million people worldwide suffer from painful and activity-limiting osteoarthritis of the hip or knee. Many patients experience insufficient pain relief or side effects with current treatment, which today usually consist of NSAIDs or opiates and there is a great need for more effective and better tolerated drugs in this field.